Navigation Links
Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
Date:10/11/2010

her self-limiting or readily managed with an inhaled bronchodilator.

The CRL also raised issues relating to the suitability of the stability studies undertaken by Alexza and certain other items relating to the FDA's recently completed pre-approval manufacturing inspection.  Because AZ-004 incorporates a novel delivery system, the CRL also included input from FDA's Center for Devices and Radiological Health (CDRH).  CDRH requested a human factors study and related analysis to validate that the product can be used effectively in the proposed clinical setting.  CDRH also requested further bench testing of the product under an additional "worst-case" manufacturing scenario.About Valeant Pharmaceuticals International, Inc.Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Caution Regarding Forward-Looking InformationTo the extent any statements made in this document contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and may be forward-looking information as defined under applicable Canadian securities legislation (collectively, "forward-looking statements").

These forward-looking statements relate to, among other things, future interactions with FDA with respect to AZ-004.  Forward-looking statements can generally be identified by the use of words such as "believe", "anticipate", "expect", "estimate", "intend", "continue", "plan", "project", "will", "may", "should", "could", "would", "target", "
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... A new Manhattan Research study, ... finds that members of pharmacy and therapeutics ... and pharmacy benefits managers (PBMs) are shifting the ... of formulary decision makers report that they are ... decision making process today than a year ago. ...
(Date:7/14/2014)...  Clinicians at a leading cancer center in ... first in the country to commence advanced lung, ... Clinac® medical linear accelerator from Varian Medical Systems ... High Intensity Mode dose delivery capability, which is ... treatment times and deliver stereotactic body radiotherapy and ...
(Date:7/14/2014)... 14, 2014  Patients and patient advocates are rallying ... and other major pharmacy benefit managers (PBMs) begin unprecedented ... impact millions of patients who rely on compounded medicines ... pain from cancer, diabetes and other illnesses. Express Scripts ... on July 15. In a matter of ...
Breaking Medicine Technology:Digital Resources Play Critical Role in Formulary Decision Making 2Digital Resources Play Critical Role in Formulary Decision Making 3Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 2Yashoda Cancer Institute Commences Radiosurgery Treatments Using Varian Clinac Linear Accelerator 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 2Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 3Patients Join to Fight Major Cuts in Prescription Coverage Says Patients and Physicians for Rx Access 4
... SOUTHAMPTON, England, June 29 Vantia ... drugs,targeting large, underserved medical markets, announces positive results ... development compound VA106483 for,nocturia. The trial showed that ... sustained anti-diuretic effect in patients, as determined by,increased ...
... England and TOKYO, June 29 , ... Sosei Group Corporation ("Sosei"; TSE Mothers ... commencement of a Phase III,clinical study by Novartis, with NVA237, ... obstructive pulmonary disease,(COPD). NVA237 is a dry powder formulation for ...
Cached Medicine Technology:Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4
(Date:7/14/2014)... July 14, 2014 Felicity Philp was diagnosed ... 29 years old. Instead of letting her health issues decrease ... food she was eating and began to see a difference ... two friends and business partners, Julie Reardon and Kate Owen, ... help others with this lifestyle change as well. In their ...
(Date:7/14/2014)... Georgia State University is starting four new ... round of its Second Century Initiative, aiming to ... performance. , The Second Century Initiative (2CI) ... to the university, with the goal of building ... significance. , “With the fifth round of the ...
(Date:7/14/2014)... , Scientists funded by the National Institutes of Health ... esophagitis (EoE), an inflammatory disease characterized by high ... Their findings suggest that several genes are involved in ... and often is associated with food allergies. The findings ... the esophagus. The work was supported in part by ...
(Date:7/14/2014)... PA, July 14, 2014 The inability to ignore ... often experienced by individuals diagnosed with schizophrenia, reports a ... Psychiatry . , Our brains are usually good at ... learn and filtering out the "noise" or thoughts that ... related in part to a problem with this filtering ...
(Date:7/14/2014)... Hicksville and Hauppauge, NY (PRWEB) July 14, 2014 ... York (RGONY), with offices in Hicksville and Hauppauge, ... intravitreal implant) as a long-lasting treatment for diabetic ... by Allergan, recently obtained an additional FDA-approved indication ... previously approved by the FDA in 2009 for ...
Breaking Medicine News(10 mins):Health News:Women Changing Lives Through Food 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 2Health News:Georgia State Starts Four Innovative Research Groups Through Fifth Round of Its Second Century Initiative 3Health News:Scientists deepen genetic understanding of eosinophilic esophagitis 2Health News:'Noisy' memory in schizophrenia 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 3
... ... ... ... ...
... who have both diabetes and major depression are more than ... diabetes only, according to a study published in the recent ... the progressive decline of thinking and reasoning abilities. These can ... the past, personality changes, and not recognizing familiar people. ...
... researchers say , FRIDAY, March 5 (HealthDay News) -- Freezing ... mice, a new study has found. , Researchers tested two ... applying a cold probe to the tumor, but one method ... the other takes a few minutes. The mice that received ...
... ... ... ... ...
... , ... ... ... ...
... report released today by Rice University,s Jones Graduate School of ... since October 2009, current Toyota owners are not yet wavering ... The rigorous survey-based study of a national sample ... satisfaction with their vehicles, quality was equally high among Toyota ...
Cached Medicine News:Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 2Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 3Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 4Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 5Health News:Pennsylvania to Observe 'Problem Gambling Awareness Week'; Remind Residents of Available Counseling and Treatment Services 6Health News:Major depression more than doubles risk of dementia among adults with diabetes 2Health News:Major depression more than doubles risk of dementia among adults with diabetes 3Health News:Freezing Technique May Stop Breast Cancer 2Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 2Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 3Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 4Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 5Health News:COPPERTONE(R) Solar Research Center Unveils Studies on Efficacy of Topical Antioxidants in Sunscreens at 2010 Annual Meeting of The American Academy of Dermatology 6Health News:Summit Seeks to Spark Call to Action on Facing World's Biggest Challenges 2Health News:Summit Seeks to Spark Call to Action on Facing World's Biggest Challenges 3Health News:Summit Seeks to Spark Call to Action on Facing World's Biggest Challenges 4Health News:Summit Seeks to Spark Call to Action on Facing World's Biggest Challenges 5Health News:Survey: Toyota owners maintain high overall satisfaction despite recalls 2
Disposable Feather Blades, 50 per pack...
Knife sharpening back for Standard Knife, C Profile...
... The Cryostage freezing stage is a refrigerated design ... holder, primarily for use with the 8000 sledge ... sledge microtomes. ,The refrigerated stage gives a large ... surface is ridged to provide good adhesion between ...
... necessary to cool a specimen below room temperature. ... most microtomes and will permit specimen cooling from ... The equipment consists of a cooling stage and ... suited for operation with a base sledge microtome, ...
Medicine Products: